GlassScriptPhysician profile
David Roodhuyzen
NPI 1770710964
$335.49
in general payments reported to CMS, 2019-2025
11 companies · $70.31 in 2025
The $70.31 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $55.09 · 2023: $59.39 · 2024: $151 · 2025: $70.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $280.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $70.12 | 2023-2025 | Fetroja |
| Abbvie INC. | $48.05 | 2024 | |
| Access Pro Medical, LLC | $31.93 | 2022 | |
| Teleflex LLC | $27.00 | 2024 | Arrow |
| Csl Behring | $25.65 | 2023 | Berinert |
| Alafair Biosciences, INC. | $25.39 | 2024 | Versawrap |
| Atricure, INC. | $24.47 | 2025 | Atricure Cryoice Cryosphere Cryoablation System |
| Alcresta Therapeutics, INC. | $23.16 | 2022 | |
| Davol INC. | $23.15 | 2024 | Arista Ah Flexitip |
| Kci USA, INC. | $20.64 | 2023 | V.A.C. Veraflo, V.A.C.Ulta, Abthera Advance |
| Acera Surgical, INC. | $15.93 | 2025 | Restrata Wound Matrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Roodhuyzen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.